Gene silencing

Types

Transcriptional

• Genomic Imprinting
• Paramutation
• Transposon silencing (or Histone Modifications)
• Transgene silencing
• Position effect
• RNA-directed DNA methylation

Post-transcriptional

• RNA interference
• RNA silencing
• Nonsense mediated decay

Meiotic

• Transvection
• Meiotic silencing of unpaired DNA

Research methods

Antisense oligonucleotides

Antisense oligonucleotides were discovered in 1978 by Paul Zamecnik and Mary Stephenson. Oligonucleotides, which are short nucleic acid fragments, bind to complementary target mRNA molecules when added to the cell. These molecules can be composed of single-stranded DNA or RNA and are generally 13–25 nucleotides long. The antisense oligonucleotides can affect gene expression in two ways: by using an RNase H-dependent mechanism or by using a steric blocking mechanism. RNase H-dependent oligonucleotides cause the target mRNA molecules to be degraded, while steric-blocker oligonucleotides prevent translation of the mRNA molecule. The majority of antisense drugs function through the RNase H-dependent mechanism, in which RNase H hydrolyzes the RNA strand of the DNA/RNA heteroduplex. expression.

Ribozymes

Ribozymes are catalytic RNA molecules used to inhibit gene expression. These molecules work by cleaving mRNA molecules, essentially silencing the genes that produced them. Sidney Altman and Thomas Cech first discovered catalytic RNA molecules, RNase P and group II intron ribozymes, in 1989 and won the Nobel Prize for their discovery. Several types of ribozyme motifs exist, including hammerhead, hairpin, hepatitis delta virus, group I, group II, and RNase P ribozymes. Hammerhead, hairpin, and hepatitis delta virus (HDV) ribozyme motifs are generally found in viruses or viroid RNAs. These motifs are able to self-cleave a specific phosphodiester bond on an mRNA molecule. Lower eukaryotes and a few bacteria contain group I and group II ribozymes. These motifs can self-splice by cleaving and joining phosphodiester bonds. The last ribozyme motif, the RNase P ribozyme, is found in Escherichia coli and is known for its ability to cleave the phosphodiester bonds of several tRNA precursors when joined to a protein cofactor.

The general catalytic mechanism used by ribozymes is similar to the mechanism used by protein ribonucleases. These catalytic RNA molecules bind to a specific site and attack the neighboring phosphate in the RNA backbone with their 2' oxygen, which acts as a nucleophile, resulting in the formation of cleaved products with a 2'3'-cyclic phosphate and a 5' hydroxyl terminal end.

RNA interference

RNA interference (RNAi) is a natural process used by cells to regulate gene expression. It was discovered in 1998 by Andrew Fire and Craig Mello, who won the Nobel Prize for their discovery in 2006. The process to silence genes first begins with the entrance of a double-stranded RNA (dsRNA) molecule into the cell, which triggers the RNAi pathway. With the cleavage or translational repression of the mRNA molecules, the genes that form them are rendered essentially inactive. Arrowhead, Discerna, and Persomics, among others.

Three prime untranslated regions and microRNAs

Main article: Three prime untranslated region

Main article: MicroRNA

The three prime untranslated regions (3'UTRs) of messenger RNAs (mRNAs) often contain regulatory sequences that post-transcriptionally cause gene silencing. Such 3'-UTRs often contain both binding sites for microRNAs (miRNAs) as well as for regulatory proteins. By binding to specific sites within the 3'-UTR, a large number of specific miRNAs decrease gene expression of their particular target mRNAs by either inhibiting translation or directly causing degradation of the transcript, using a mechanism similar to RNA interference (see MicroRNA). The 3'-UTR also may have silencer regions that bind repressor proteins that inhibit the expression of an mRNA.

The 3'-UTR often contains microRNA response elements (MREs). MREs are sequences to which miRNAs bind and cause gene silencing. These are prevalent motifs within 3'-UTRs. Among all regulatory motifs within the 3'-UTRs (e.g. including silencer regions), MREs make up about half of the motifs.

As of 2014, the miRBase web site, an archive of miRNA sequences and annotations, listed 28,645 entries in 233 biologic species. Of these, 1,881 miRNAs were in annotated human miRNA loci. miRNAs were predicted to each have an average of about four hundred target mRNAs (causing gene silencing of several hundred genes). Freidman et al. estimate that 45,000 miRNA target sites within human mRNA 3'UTRs are conserved above background levels, and 60% of human protein-coding genes have been under selective pressure to maintain pairing to miRNAs.

Direct experiments show that a single miRNA can reduce the stability of hundreds of unique mRNAs. Other experiments show that a single miRNA may repress the production of hundreds of proteins, but that this repression often is relatively mild (less than 2-fold).

The effects of miRNA dysregulation of gene expression seem to be important in cancer. For instance, in gastrointestinal cancers, nine miRNAs have been identified as epigenetically altered and effective in down regulating DNA repair enzymes.

The effects of miRNA dysregulation of gene expression also seem to be important in neuropsychiatric disorders, such as schizophrenia, bipolar disorder, major depression, Parkinson's disease, Alzheimer's disease and autism spectrum disorders.

Applications

Medical research

Gene silencing techniques have been widely used by researchers to study genes associated with disorders. These disorders include cancer, infectious diseases, respiratory diseases, and neurodegenerative disorders. Gene silencing is also currently being used in drug discovery efforts, such as synthetic lethality, high-throughput screening, and miniaturized RNAi screens.

Cancer

RNA interference has been used to silence genes associated with several cancers. In in vitro studies of chronic myelogenous leukemia (CML), siRNA was used to cleave the fusion protein, BCR-ABL, which prevents the drug Gleevec (imatinib) from binding to the cancer cells. Cleaving the fusion protein reduced the amount of transformed hematopoietic cells that spread throughout the body by increasing the sensitivity of the cells to the drug.

Receptors involved in mitogenic pathways that lead to the increased production of cancer cells there have also been targeted by siRNA molecules. The chemokine receptor chemokine receptor 4 (CXCR4), associated with the proliferation of breast cancer, was cleaved by siRNA molecules that reduced the number of divisions commonly observed by the cancer cells. Researchers have also used siRNAs to selectively regulate the expression of cancer-related genes. Antiapoptotic proteins, such as clusterin and survivin, are often expressed in cancer cells. Clusterin and survivin-targeting siRNAs were used to reduce the number of antiapoptotic proteins and, thus, increase the sensitivity of the cancer cells to chemotherapy treatments.

Infectious disease

Viruses

Viral genes and host genes that are required for viruses to replicate or enter the cell, or that play an important role in the life cycle of the virus are often targeted by antiviral therapies. RNAi has been used to target genes in several viral diseases, such as the human immunodeficiency virus (HIV) and hepatitis.{{cite journal|author3-link= Anastasia Khvorova | vauthors = Wilson JA, Jayasena S, Khvorova A, Sabatinos S, Rodrigue-Gervais IG, Arya S, Sarangi F, Harris-Brandts M, Beaulieu S, Richardson CD | title = RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 100 | issue = 5 | pages = 2783–8 | date = March 2003 | pmid = 12594341 | doi = 10.1073/pnas.252758799 | bibcode = 2003PNAS..100.2783W | pmc=151418| doi-access = free }} In particular, siRNA was used to silence the primary HIV receptor chemokine receptor 5 (CCR5). This prevented the virus from entering the human peripheral blood lymphocytes and the primary hematopoietic stem cells. A similar technique was used to decrease the amount of the detectable virus in hepatitis B and C infected cells. In hepatitis B, siRNA silencing was used to target the surface antigen on the hepatitis B virus and led to a decrease in the number of viral components. In addition, siRNA techniques used in hepatitis C were able to lower the amount of the virus in the cell by 98%.

RNA interference has been in commercial use to control virus diseases of plants for over 20 years (see Plant disease resistance). In 1986–1990, multiple examples of "coat protein-mediated resistance" against plant viruses were published, before RNAi had been discovered. In 1993, work with tobacco etch virus first demonstrated that host organisms can target specific virus or mRNA sequences for degradation, and that this activity is the mechanism behind some examples of virus resistance in transgenic plants. The discovery of small interfering RNAs (the specificity determinant in RNA-mediated gene silencing) also utilized virus-induced post-transcriptional gene silencing in plants. By 1994, transgenic squash varieties had been generated expressing coat protein genes from three different viruses, providing squash hybrids with field-validated multiviral resistance that remain in commercial use at present. Potato lines expressing viral replicase sequences that confer resistance to potato leafroll virus were sold under the trade names NewLeaf Y and NewLeaf Plus, and were widely accepted in commercial production in 1999–2001, until McDonald's Corp. decided not to purchase GM potatoes and Monsanto decided to close their NatureMark potato business. Another frequently cited example of virus resistance mediated by gene silencing involves papaya, where the Hawaiian papaya industry was rescued by virus-resistant GM papayas produced and licensed by university researchers rather than a large corporation. These papayas also remain in use at present, although not without significant public protest, which is notably less evident in medical uses of gene silencing.

Gene silencing techniques have also been used to target other viruses, such as the human papilloma virus, the West Nile virus, and the Tulane virus. The E6 gene in tumor samples retrieved from patients with the human papilloma virus was targeted and found to cause apoptosis in the infected cells. Plasmid siRNA expression vectors used to target the West Nile virus were also able to prevent the replication of viruses in cell lines. In addition, siRNA has been found to be successful in preventing the replication of the Tulane virus, part of the virus family Caliciviridae, by targeting both its structural and non-structural genes. By targeting the NTPase gene, one dose of siRNA 4 hours pre-infection was shown to control Tulane virus replication for 48 hours post-infection, reducing the viral titer by up to 2.6 logarithms. Although the Tulane virus is species-specific and does not affect humans, it has been shown to be closely related to the human norovirus, which is the most common cause of acute gastroenteritis and food-borne disease outbreaks in the United States. Human noroviruses are notorious for being difficult to study in the laboratory, but the Tulane virus offers a model through which to study this family of viruses for the clinical goal of developing therapies that can be used to treat illnesses caused by human norovirus.

Bacteria

Unlike viruses, bacteria are not as susceptible to silencing by siRNA. This is largely due to how bacteria replicate. Bacteria replicate outside of the host cell and do not contain the necessary machinery for RNAi to function. For instance, siRNA was used to reduce the amount of pro-inflammatory cytokines expressed in the cells of mice treated with lipopolysaccharide (LPS). The reduced expression of the inflammatory cytokine, tumor necrosis factor α (TNFα), in turn, caused a reduction in the septic shock felt by the LPS-treated mice. In addition, siRNA was used to prevent the bacteria, Psueomonas aeruginosa, from invading murine lung epithelial cells by knocking down the caveolin-2 (CAV2) gene. Thus, though bacteria cannot be directly targeted by siRNA mechanisms, they can still be affected by siRNA when the components involved in the bacterial infection are targeted.

Respiratory diseases

Ribozymes, antisense oligonucleotides, and more recently RNAi have been used to target mRNA molecules involved in asthma. These experiments have suggested that siRNA may be used to combat other respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Mucus secretion was found to be reduced when the transforming growth factor (TGF)-α was targeted by siRNA in NCI-H292 human airway epithelial cells. In addition to mucus hypersecretion, chronic inflammation and damaged lung tissue are characteristic of COPD and asthma. The transforming growth factor TGF-β is thought to play a role in these manifestations. As a result, when interferon (IFN)-γ was used to knock down TGF-β, fibrosis of the lungs, caused by damage and scarring to lung tissue, was improved.

Neurodegenerative disorders

Huntington's disease

Huntington's disease (HD) results from a mutation in the huntingtin gene that causes an excess of CAG repeats. The gene then forms a mutated huntingtin protein with polyglutamine repeats near the amino terminus. This disease is incurable and known to cause motor, cognitive, and behavioral deficits. Researchers have been looking to gene silencing as a potential therapeutic for HD.

Gene silencing can be used to treat HD by targeting the mutant huntingtin protein. The mutant huntingtin protein has been targeted through gene silencing that is allele specific using allele specific oligonucleotides. In this method, the antisense oligonucleotides are used to target single nucleotide polymorphism (SNPs), which are single nucleotide changes in the DNA sequence, since HD patients have been found to share common SNPs that are associated with the mutated huntingtin allele. It has been found that approximately 85% of patients with HD can be covered when three SNPs are targeted. In addition, when antisense oligonucleotides were used to target an HD-associated SNP in mice, there was a 50% decrease in the mutant huntingtin protein.

Non-allele specific gene silencing using siRNA molecules has also been used to silence the mutant huntingtin proteins. Through this approach, instead of targeting SNPs on the mutated protein, all of the normal and mutated huntingtin proteins are targeted. When studied in mice, it was found that siRNA could reduce the normal and mutant huntingtin levels by 75%. At this level, they found that the mice developed improved motor control and a longer survival rate when compared to the controls. Thus, gene silencing methods may prove to be beneficial in treating HD.

Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease, is a motor neuron disease that affects the brain and spinal cord. The disease causes motor neurons to degenerate, which eventually leads to neuron death and muscular degeneration. Hundreds of mutations in the Cu/Zn superoxide dismutase (SOD1) gene have been found to cause ALS. Gene silencing has been used to knock down the SOD1 mutant that is characteristic of ALS. In specific, siRNA molecules have been successfully used to target the SOD1 mutant gene and reduce its expression through allele-specific gene silencing.

Therapeutics challenges

There are several challenges associated with gene silencing therapies, including delivery and specificity for targeted cells. For instance, for treatment of neurodegenerative disorders, molecules for a prospective gene silencing therapy must be delivered to the brain. The blood–brain barrier makes it difficult to deliver molecules into the brain through the bloodstream by preventing the passage of the majority of molecules that are injected or absorbed into the blood. Thus, researchers have found that they must directly inject the molecules or implant pumps that push them into the brain.

Once inside the brain, however, the molecules must move inside of the targeted cells. In order to efficiently deliver siRNA molecules into the cells, viral vectors can be used. Nevertheless, this method of delivery can also be problematic as it can elicit an immune response against the molecules. In addition to delivery, specificity has also been found to be an issue in gene silencing. Both antisense oligonucleotides and siRNA molecules can potentially bind to the wrong mRNA molecule. Thus, researchers are searching for more efficient methods to deliver and develop specific gene silencing therapeutics that are still safe and effective.

Food

Main article: Arctic Apples

Arctic Apples are a suite of trademarked apples that contain a nonbrowning trait created by using gene silencing to reduce the expression of polyphenol oxidase (PPO). It is the first approved food product to use this technique.

References

References

1. Redberry, Grace. (2006). "Gene silencing : new research". Nova Science Publishers.
2. "Gene Silencing". National Center for Biotechnology Information.
3. (March 2004). "RNAi: What's all the noise about gene silencing?". Environmental Health Perspectives.
4. (December 7, 2006). "RNA interference: learning gene knock-down from cell physiology". Journal of Translational Medicine.
5. (September 2023}}. Methods using gene silencing are often considered better than gene knockouts{{Cite web). "What is the difference between gene silencing and gene knockout? {{!}} AAT Bioquest".
6. (2020-02-05). "Efficient Gene Silencing by Adenine Base Editor-Mediated Start Codon Mutation". Molecular Therapy.
7. (February 2012). "RNA therapeutics: beyond RNA interference and antisense oligonucleotides". Nature Reviews. Drug Discovery.
8. (March 2002). "Antisense oligonucleotides: basic concepts and mechanisms". Molecular Cancer Therapeutics.
9. (March 2004). "Antisense and RNA interference approaches to target validation in pain research". Current Opinion in Drug Discovery & Development.
10. Phylactou, L.. (1 September 1998). "Ribozymes as therapeutic tools for genetic disease". Human Molecular Genetics.
11. (October 2012). "Sidney Altman--Nobel laureate for work with RNA". Mayo Clinic Proceedings.
12. (1 June 2001). "Ribozyme structures and mechanisms". Annual Review of Biophysics and Biomolecular Structure.
13. (2007). "Biological aging methods and protocols". Humana Press.
14. "RNA Interference Fact Sheet". National Institutes of Health.
15. (2013). "Molecular mechanisms of RNA interference". Annual Review of Biophysics.
16. "The Second Coming of RNAi {{!}} The Scientist Magazine®".
17. "Products {{!}} Persomics".
18. miRBase.org
19. (January 2009). "Most mammalian mRNAs are conserved targets of microRNAs". Genome Research.
20. (February 2005). "Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs". Nature.
21. (September 2008). "Widespread changes in protein synthesis induced by microRNAs". Nature.
22. (September 2008). "The impact of microRNAs on protein output". Nature.
23. (July 2011). "Mechanisms and role of microRNA deregulation in cancer onset and progression". Genetics and Molecular Biology.
24. (May 2015). "Epigenetic reduction of DNA repair in progression to gastrointestinal cancer". World Journal of Gastrointestinal Oncology.
25. (2014). "Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders". Frontiers in Cellular Neuroscience.
26. (2012). "The Emerging Role of microRNAs in Schizophrenia and Autism Spectrum Disorders". Frontiers in Psychiatry.
27. (August 2015). "MicroRNA and Posttranscriptional Dysregulation in Psychiatry". Biological Psychiatry.
28. (June 2004). "Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin". The Journal of Clinical Investigation.
29. (November 2002). "Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways". Proceedings of the National Academy of Sciences of the United States of America.
30. (January 2005). "CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo". Cancer Gene Therapy.
31. (March 2004). "Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo". Molecular Cancer Therapeutics.
32. (October 2004). "siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth". International Journal of Oncology.
33. (April 2003). "Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells". Clinical Cancer Research.
34. (December 2004). "Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains". Journal of Virology.
35. (January 2003). "Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5". Proceedings of the National Academy of Sciences of the United States of America.
36. (August 2003). "Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs". Molecular Therapy.
37. (November 2003). "Small interfering RNA inhibits hepatitis B virus replication in mice". Molecular Therapy.
38. (January 2003). "Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs". Proceedings of the National Academy of Sciences of the United States of America.
39. (June 2004). "Interfering with hepatitis C virus RNA replication". Virus Research.
40. (1990). "Coat Protein-Mediated Resistance Against Virus Infection". Annual Review of Phytopathology.
41. (2005). "Plant pathology and RNAi: a brief history". Annual Review of Phytopathology.
42. (December 1993). "Induction of a Highly Specific Antiviral State in Transgenic Plants: Implications for Regulation of Gene Expression and Virus Resistance". The Plant Cell.
43. (October 1999). "A species of small antisense RNA in posttranscriptional gene silencing in plants". Science.
44. (2004). "The Potato Story". AgBioForum.
45. (2002). "Virus Coat Protein Transgenic Papaya Provides Practical Control ofPapaya ringspot virusin Hawaii". Plant Disease.
46. "Papaya: A GMO success story".
47. (19 December 2013). "Papaya in the Crosshairs: A Heated Island Battle Over GMOs - Modern Farmer".
48. (September 2003). "siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells". Oncogene.
49. (September 2003). "The utility of siRNA transcripts produced by RNA polymerase i in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses". Virology.
50. (January 2013). "Inhibition of Tulane virus replication in vitro with RNA interference". Journal of Medical Virology.
51. (2018-12-21). "Norovirus Overview". Center for Disease Control and Prevention.
52. (September 2003). "Interfering with disease: opportunities and roadblocks to harnessing RNA interference". Trends in Molecular Medicine.
53. (August 2005). "RNA interference: from gene silencing to gene-specific therapeutics". Pharmacology & Therapeutics.
54. (February 2005). "Pseudomonas invasion of type I pneumocytes is dependent on the expression and phosphorylation of caveolin-2". The Journal of Biological Chemistry.
55. (September 2007). "A review of antisense therapeutic interventions for molecular biological targets in asthma". Biologics: Targets and Therapy.
56. (August 2004). "Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor-alpha-converting enzyme in human airway epithelial (NCI-H292) cells". American Journal of Physiology. Lung Cellular and Molecular Physiology.
57. (November 1999). "Inflammation and repair processes in chronic obstructive pulmonary disease". American Journal of Respiratory and Critical Care Medicine.
58. (2004). "Epithelial cells and fibroblasts: structural repair and remodelling in the airways". Paediatric Respiratory Reviews.
59. "Pulmonary Fibrosis". Mayo Clinic.
60. (Sep–Oct 1995). "Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression". Experimental Lung Research.
61. (2012-04-05). "Gene Silencing". Stanford University.
62. (September 2012). "RNAi-based therapies for Huntington's disease: delivery challenges and opportunities". Therapeutic Delivery.
63. (August 2009). "Progress and challenges in RNA interference therapy for Huntington disease". Archives of Neurology.
64. "What is ALS?". The ALS Association.
65. (February 2008). "Double-mismatched siRNAs enhance selective gene silencing of a mutant ALS-causing allele". Acta Pharmacologica Sinica.
66. Boulis, Nicholas. "Gene Therapy for Motor Neuron Disease". Society for Neuroscience.
67. [https://www.aphis.usda.gov/sites/default/files/10_16101p.pdf Petition for Determination of Nonregulated Status: Arctic™ Apple (Malus x domestica) Events GD743 and GS784]. ''United States Department of Agriculture – Animal and Plant Health Inspection Service''. Retrieved 2012-08-03.
68. "Apple-to-apple transformation". Okanagan Specialty Fruits.